|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CA2915412A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
JP6501270B2
(ja)
|
2013-03-14 |
2019-04-17 |
ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ |
標的化剤抗体抱合体およびその使用
|
|
JP6693872B2
(ja)
*
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス,インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
KR102488220B1
(ko)
|
2013-09-25 |
2023-01-12 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
MX379030B
(es)
|
2013-12-17 |
2025-03-10 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
KR102466591B1
(ko)
*
|
2014-01-31 |
2022-11-14 |
싸이톰스 테라퓨틱스, 인크. |
마트립타제 및 u-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3221356B1
(en)
|
2014-11-20 |
2020-09-02 |
F.Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules against folr1 and cd3
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
WO2016182064A1
(ja)
*
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
CA2991976A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
KR102784293B1
(ko)
*
|
2015-09-21 |
2025-03-20 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
|
CA3002573A1
(en)
*
|
2015-11-03 |
2017-05-11 |
Ambrx, Inc. |
Anti-cd3 antibodies and their uses
|
|
EP3903818A1
(en)
|
2015-11-19 |
2021-11-03 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
|
CN109069635B
(zh)
*
|
2016-02-04 |
2023-09-26 |
斯克利普斯研究所 |
人源化抗cd3抗体、偶联物及其用途
|
|
US10745478B2
(en)
*
|
2016-02-19 |
2020-08-18 |
Dignity Health |
Antibody fusion protein and related compositions for targeting cancer
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
LT3433280T
(lt)
*
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
MA43724B1
(fr)
*
|
2016-03-22 |
2023-06-28 |
Hoffmann La Roche |
Molécules bispécifiques de cellules t activées par une protéase
|
|
WO2017162890A1
(en)
|
2016-03-25 |
2017-09-28 |
Biomunex Pharmaceuticals |
Binding molecules to cd38 and pd-l1
|
|
SG11201809316XA
(en)
*
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
KR102590454B1
(ko)
|
2016-07-07 |
2023-10-17 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
MY200988A
(en)
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
CN106632681B
(zh)
*
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
BR112019008223A2
(pt)
*
|
2016-11-03 |
2019-07-16 |
Bristol-Myers Squibb Company |
anticorpos anti-ctla-4 ativáveis e usos dos mesmos
|
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
TW202235438A
(zh)
|
2016-11-28 |
2022-09-16 |
日商中外製藥股份有限公司 |
能夠調節配體結合活性的配體結合分子
|
|
MX2019005756A
(es)
|
2016-11-28 |
2019-08-14 |
Chugai Pharmaceutical Co Ltd |
Dominio de union al antigeno y polipeptido que incluye seccion de transporte.
|
|
EP3551034A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
JP7141407B2
(ja)
*
|
2016-12-13 |
2022-09-22 |
エフ.ホフマン-ラ ロシュ アーゲー |
腫瘍試料における標的抗原の存在を決定する方法
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
JP2020508663A
(ja)
*
|
2017-02-22 |
2020-03-26 |
アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. |
癌の治療のための組成物及び方法
|
|
US10093731B2
(en)
|
2017-02-24 |
2018-10-09 |
Kindred Biosciences, Inc. |
Anti-IL31 antibodies for veterinary use
|
|
WO2018178101A1
(en)
|
2017-03-27 |
2018-10-04 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
WO2018191438A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
AU2018280681B2
(en)
*
|
2017-06-05 |
2025-01-23 |
Numab Therapeutics AG |
Novel anti-CD3 antibodies
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
WO2019005637A2
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
|
|
WO2019018828A1
(en)
|
2017-07-20 |
2019-01-24 |
Cytomx Therapeutics, Inc. |
METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
WO2019045856A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Systimmune, Inc. |
ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM
|
|
WO2019042153A1
(zh)
*
|
2017-09-01 |
2019-03-07 |
四川科伦博泰生物医药股份有限公司 |
重组双特异性抗体
|
|
WO2019051102A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
|
US11472889B2
(en)
|
2017-10-14 |
2022-10-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
EP3719035A4
(en)
*
|
2017-11-28 |
2021-09-01 |
Chugai Seiyaku Kabushiki Kaisha |
POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION
|
|
TWI880235B
(zh)
|
2017-11-28 |
2025-04-11 |
日商中外製藥股份有限公司 |
可調整配體結合活性的配體結合分子
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
CN107880129B
(zh)
*
|
2017-12-28 |
2021-01-15 |
广州市鲁诚生物科技有限公司 |
一种重组抗体及其制备方法
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
SG11202007572VA
(en)
*
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス,インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
CN110305217B
(zh)
*
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
IL277863B2
(en)
|
2018-04-11 |
2026-02-01 |
Inhibrx Inc |
Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
|
|
EP3788077A1
(en)
|
2018-05-02 |
2021-03-10 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
CN113840832A
(zh)
|
2018-05-14 |
2021-12-24 |
狼人治疗公司 |
可活化白介素-2多肽及其使用方法
|
|
US12534734B2
(en)
*
|
2018-05-15 |
2026-01-27 |
Drive Therapeutics Llc |
Stem-loop compositions and methods for inhibiting interleukin-8
|
|
DK3797121T3
(da)
*
|
2018-05-23 |
2024-07-08 |
Pfizer |
Antistoffer, der er specifikke for CD3, og anvendelser deraf
|
|
JPWO2019230868A1
(ja)
|
2018-05-30 |
2021-06-24 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
JP7414736B2
(ja)
|
2018-05-30 |
2024-01-16 |
中外製薬株式会社 |
アグリカン結合ドメインおよび運搬部分を含むポリペプチド
|
|
WO2019232323A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Board Of Regents, The University Of Texas System |
Bi-specific antibodies and use thereof
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
CN112513081A
(zh)
*
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
TW202016144A
(zh)
*
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
EP3829642A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Pharmaceutical formulations of masked antibodies
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113518647A
(zh)
|
2018-10-11 |
2021-10-19 |
印希比股份有限公司 |
5t4单域抗体及其治疗性组合物
|
|
FI3880675T3
(fi)
|
2018-11-12 |
2024-12-09 |
Debiopharm Int Sa |
Antibioottiyhdisteitä, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia koostumuksia ja niiden käyttöjä
|
|
WO2020106757A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
SG11202105476XA
(en)
|
2018-12-06 |
2021-06-29 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
KR20210142638A
(ko)
*
|
2019-02-22 |
2021-11-25 |
우한 이지 바이오파마 씨오., 엘티디. |
Cd3 항원 결합 단편 및 이의 응용
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
JP2022525594A
(ja)
|
2019-03-15 |
2022-05-18 |
ボルト バイオセラピューティクス、インコーポレーテッド |
Her2を標的とする免疫結合体
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
EP3966250A4
(en)
*
|
2019-05-07 |
2022-11-23 |
Immunorizon Ltd. |
PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
JPWO2020246563A1
(enExample)
|
2019-06-05 |
2020-12-10 |
|
|
|
US20230220105A1
(en)
*
|
2019-06-06 |
2023-07-13 |
Janux Therapeutics, Inc. |
Tumor activated t cell engagers and methods of use thereof
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ, インコーポレイテッド |
Cd22及びcd3に結合する多重特異性重鎖抗体
|
|
BR112021026089A2
(pt)
*
|
2019-06-26 |
2022-03-22 |
Amunix Pharmaceuticals Inc |
Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
|
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
|
GB201912681D0
(en)
*
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
BR112022004995A2
(pt)
|
2019-09-18 |
2022-06-21 |
Lamkap Bio Alpha AG |
Anticorpos biespecíficos contra ceacam5 e cd3
|
|
CN114650844A
(zh)
*
|
2019-09-23 |
2022-06-21 |
西托姆克斯治疗公司 |
抗cd47抗体、可活化抗cd47抗体及其使用方法
|
|
CN118420771A
(zh)
*
|
2019-11-06 |
2024-08-02 |
西雅图免疫公司 |
制导和导航控制蛋白及其制备和使用方法
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
CN121197633A
(zh)
|
2019-12-13 |
2025-12-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
EP4090686A4
(en)
*
|
2020-01-17 |
2024-03-27 |
Immune Targeting Inc. |
PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
|
|
IL294879A
(en)
|
2020-01-29 |
2022-09-01 |
Inhibrx Inc |
Monodomain antibodies of cd28 and their multivalent and multispecific constructs
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
|
JP7641292B2
(ja)
*
|
2020-03-03 |
2025-03-06 |
システィミューン, インク. |
抗cd19抗体、その使用方法及び製造方法
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
AR125758A1
(es)
*
|
2020-04-04 |
2023-08-09 |
Janux Therapeutics Inc |
Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
|
|
CA3174665A1
(en)
|
2020-04-09 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Compositions containing activatable antibodies
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
IL297412A
(en)
*
|
2020-05-04 |
2022-12-01 |
Immunorizon Ltd |
Precursor tri-specific antibody constructs and methods of use thereof
|
|
KR20260042619A
(ko)
|
2020-08-11 |
2026-03-31 |
재눅스 테라퓨틱스 인크. |
절단 가능한 링커 조성물 및 방법
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
WO2022046658A1
(en)
*
|
2020-08-24 |
2022-03-03 |
Janux Therapeutics, Inc. |
Antibodies targeting trop2 and cd3 and uses thereof
|
|
AU2021333577B2
(en)
|
2020-08-25 |
2025-09-11 |
Gilead Sciences, Inc. |
Multi-specific antigen binding molecules targeting HIV and methods of use
|
|
US12116411B2
(en)
*
|
2020-11-03 |
2024-10-15 |
Abzyme Therapeutics Llc |
Antibodies binding to human CD3 at acidic pH
|
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
KR20230095113A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
JP7853992B2
(ja)
*
|
2020-11-10 |
2026-04-30 |
上海齊魯制藥研究中心有限公司 |
クローディン18a2及びcd3に対する二重特異性抗体及びその使用
|
|
JP2023553323A
(ja)
*
|
2020-11-25 |
2023-12-21 |
エクシリオ デベロップメント, インコーポレイテッド |
腫瘍特異的に切断可能なリンカー
|
|
EP4259177A4
(en)
*
|
2020-12-08 |
2024-11-06 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
EP4259193A4
(en)
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
WO2022150803A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Musc Foundation For Research Development |
AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
KR102671734B1
(ko)
*
|
2021-04-13 |
2024-06-04 |
건국대학교 글로컬산학협력단 |
개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
WO2022266341A1
(en)
*
|
2021-06-16 |
2022-12-22 |
Regents Of The University Of Minnesota |
Targeted adam17 blocker compounds, anti-adam17 antibodies, methods of making, and methods of using
|
|
EP4359443A4
(en)
*
|
2021-06-25 |
2026-02-25 |
Harpoon Therapeutics Inc |
Sustained-release immune cell contact proteins and processing methods
|
|
JP7720989B2
(ja)
*
|
2021-08-25 |
2025-08-08 |
システィミューン, インク. |
Egfr及びher3を標的とする二重特異性四価抗体
|
|
CN115894701A
(zh)
*
|
2021-09-30 |
2023-04-04 |
上海君实生物医药科技股份有限公司 |
结合cd3的抗体及其用途
|
|
TW202323282A
(zh)
|
2021-10-15 |
2023-06-16 |
美商賽特艾克斯生物製藥公司 |
可活化之多肽複合物
|
|
KR20240115809A
(ko)
|
2021-10-15 |
2024-07-26 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 폴리펩타이드 복합체
|
|
WO2023064955A1
(en)
|
2021-10-15 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
|
|
KR20240113514A
(ko)
|
2021-11-30 |
2024-07-22 |
다이이찌 산쿄 가부시키가이샤 |
프로테아제 분해성 마스크 항체
|
|
CN118401555A
(zh)
*
|
2021-12-09 |
2024-07-26 |
信华生物药业(广州)有限公司 |
抗体掩蔽物及其用途
|
|
US12269887B2
(en)
|
2022-01-20 |
2025-04-08 |
Regents Of The University Of Minnesota |
Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
|
|
KR20240141757A
(ko)
|
2022-02-09 |
2024-09-27 |
다이이찌 산쿄 가부시키가이샤 |
환경 응답성 마스킹 항체 및 그 이용
|
|
AU2023226005A1
(en)
|
2022-02-23 |
2024-08-29 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
CA3252619A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-CD28 and anti-PSMA antibodies
|
|
US20250333539A1
(en)
|
2022-03-23 |
2025-10-30 |
Cytomx Therapeutics, Inc. |
Activatable antigen-binding protein constructs and uses of the same
|
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
JP2025512798A
(ja)
|
2022-03-25 |
2025-04-22 |
サイトムエックス セラピューティクス,インク. |
活性化可能な二重アンカー型マスク化分子及びその使用方法
|
|
EP4504782A2
(en)
|
2022-04-01 |
2025-02-12 |
CytomX Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
US20230406927A1
(en)
*
|
2022-04-29 |
2023-12-21 |
Regents Of The University Of Minnesota |
Masked single-domain antibodies and methods thereof
|
|
EP4565250A1
(en)
|
2022-08-01 |
2025-06-11 |
CytomX Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
|
US20260015425A1
(en)
|
2022-08-01 |
2026-01-15 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
|
EP4565260A1
(en)
|
2022-08-01 |
2025-06-11 |
CytomX Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
AR130080A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Restos escindibles por proteasas, y métodos de uso de los mismos
|
|
US20260049148A1
(en)
|
2022-08-01 |
2026-02-19 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
GB202214132D0
(en)
*
|
2022-09-27 |
2022-11-09 |
Coding Bio Ltd |
CLL1 binding molecules
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
EP4615514A2
(en)
*
|
2022-11-10 |
2025-09-17 |
Janux Therapeutics, Inc. |
Antibodies targeting egfr and cd3 and uses thereof
|
|
US20240376170A1
(en)
|
2023-01-11 |
2024-11-14 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024150174A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
JP2026513839A
(ja)
|
2023-04-12 |
2026-05-01 |
サイトムエックス セラピューティクス,インク. |
マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2024216194A1
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024218162A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
WO2024243093A2
(en)
*
|
2023-05-19 |
2024-11-28 |
The Regents Of The University Of California |
Multispecific antibodies targeting cd3 and cd22
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
US20250197467A1
(en)
|
2023-08-23 |
2025-06-19 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
CN121729430A
(zh)
*
|
2023-10-11 |
2026-03-24 |
合肥安博宁生命科技有限公司 |
抗cd3可激活抗体及其用途
|
|
WO2025201240A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
|
|
WO2025230233A1
(ko)
*
|
2024-05-03 |
2025-11-06 |
국민대학교산학협력단 |
인간 cd3에 특이적인 항체 및 이의 용도
|
|
WO2025235515A1
(en)
|
2024-05-07 |
2025-11-13 |
Cytomx Therapeutics, Inc. |
Activatable polypeptide complex formulations
|
|
WO2025240659A2
(en)
|
2024-05-14 |
2025-11-20 |
Cytomx Therapeutics, Inc. |
Activatable constructs, compositions and methods
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026020161A1
(en)
|
2024-07-19 |
2026-01-22 |
Cytomx Therapeutics, Inc. |
Activatable il-12 constructs and related compositions and methods
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|
|
WO2026035650A2
(en)
|
2024-08-05 |
2026-02-12 |
Cytomx Therapeutics, Inc. |
Cleavable polypeptides and methods of use thereof
|
|
WO2026052652A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026052654A1
(en)
*
|
2024-09-03 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Cytokine receptor agonist
|
|
WO2026083296A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
|
|
WO2026083295A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
|